Sunday, May 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

RFI – Chemical Agent Countermeasure Support

by Global Biodefense Staff
May 14, 2015
Joint Project Manager Medical Countermeasure Systems

The DoD Medical Countermeasure Systems-Chemical Defense Pharmaceuticals (MCS-CDP) Joint Product Management Office  has a requirement to develop and deliver FDA licensed butyrylcholinesterase (BChE).

BChE is a bioscavenger prophylactic countermeasure against organophosphate nerve agents, binding nerve agent in the bloodstream before it can exert effects in the nervous system.

DynPort Vaccine Company LLC, a CSC company, is the prime contractor for this effort.

On behalf of DVC, the MCS-CDP JPMO is seeking interest by research or commercial entities with the capability to perform process development activities at small scale to intermediate scale in order to identify a source raw material and process to fit to the commercial scale requirements of this DoD contract.

Source raw material and historical manufacturing information will be provided by DVC.

Capability requirements include:

  • Acceptance of human plasma derived source material into the process development facility
  • Storage of the source material at -80OC (up to 50kg of starting source material per run)
  • Development and optimization of the purification process at the 1-5kg scale and 50kg scale
  • Manufacture and testing of an interim Reference Standard (RS) to support process development and optimization activities
  • Implementation of analytical methods to be used during process development and RS production effort, including but not limited to total protein, enzyme activity, and HPLC-based methods.
  • Project Management support including status meetings and monthly reports with technical, schedule and cost elements

In addition, the selected contractor must be able to meet a November 2015 down select of source material and process for commercial scale manufacturing.

Further details are available via Solicitation Number: W911QY-15-S-DAMD17.

Tags: AntitoxinsBioscavengersJPEO-CBRNDRFI

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC